RCAMU
EW icon

Rothschild & Co Asset Management US’s Edwards Lifesciences EW Stock Holding History

Rothschild & Co Asset Management US’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,468
Closed -$491K – 418
2017
Q2 		$491K Sell
12,468
-1,455
-10% -$53.1K 0.01% 524
2017
Q1 		$437K Sell
13,923
-1,926
-12% -$60.3K 0.01% 542
2016
Q4 		$495K Buy
15,849
+3,813
+32% +$124K 0.01% 529
2016
Q3 		$484K Buy
+12,036
New +$453K 0.01% 464

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Rothschild & Co Asset Management US's EW Position: Q3 2017 in Review

Rothschild & Co Asset Management US sold out of Edwards Lifesciences (EW) in Q3 2017, closing a stake of 12,468 shares — an estimated $491K sold.

Rothschild & Co Asset Management US first reported a position in EW in Q3 2016 and held it in 4 quarters. The position peaked at $495K in Q4 2016. 740 funds tracked by Wall St. Rank hold EW as of Q3 2017.

  • Rothschild & Co Asset Management US reported no remaining Edwards Lifesciences position as of Q3 2017 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 12,468 Edwards Lifesciences shares in Q3 2017, an estimated $491K.
  • Rothschild & Co Asset Management US first reported a position in Edwards Lifesciences in Q3 2016 and held it in 4 quarters.
  • Rothschild & Co Asset Management US's Edwards Lifesciences position peaked at $495K in Q4 2016.
  • 740 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2017.

Based on Rothschild & Co Asset Management US's 13F filing for Q3 2017, filed 8 Nov 2017.